Ambu (AMBU B) Aperçu de l'action
Ambu A/S, société de technologie médicale, développe, produit et vend des dispositifs médicaux aux hôpitaux, cliniques et services de secours du monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 4/6 |
| Performances passées | 5/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
AMBU B ont passé avec succès nos contrôles de risques.
AMBU B Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ambu A/S Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | DKK 68.15 |
| Plus haut sur 52 semaines | DKK 111.80 |
| Plus bas sur 52 semaines | DKK 60.45 |
| Bêta | 1.26 |
| Variation sur 1 mois | 4.77% |
| Variation sur 3 mois | -13.13% |
| Variation sur 1 an | -32.59% |
| Variation sur 3 ans | -37.93% |
| Variation sur 5 ans | -69.98% |
| Évolution depuis l'introduction en bourse | 3,879.56% |
Nouvelles et mises à jour récentes
Mise à jour du récit • May 19
AMBU B: Lower P/E Expectations Will Support Future Upside Repricing
Analysts have trimmed their price target on Ambu from DKK 110.34 to DKK 88.80, reflecting a more cautious stance following a downgrade in recent research. The revised target still assumes steady revenue growth and a lower future P/E multiple.Article d’analyse • May 09
Ambu A/S Just Missed EPS By 13%: Here's What Analysts Think Will Happen Next
As you might know, Ambu A/S ( CPH:AMBU B ) last week released its latest quarterly, and things did not turn out so...
Mise à jour du récit • May 04
AMBU B: Higher Growth And Margins Are Expected To Support Future Upside
Analysts have reduced their price target on Ambu by DKK 12. This reflects updated views on discount rates, expected revenue growth, profit margins and future P/E assumptions.Mise à jour du récit • Apr 20
AMBU B: Reset P/E Assumptions Will Support Future Upside Repricing
Ambu's analyst price target has been reduced by DKK 12 to reflect updated views on its P/E assumptions, revenue growth profile and profitability, with analysts pointing to the recent DKK 12 target cut cited in Street research. Analyst Commentary JPMorgan's DKK 12 reduction in its Ambu price target reflects a reset of P/E expectations and a more cautious stance on the company's revenue growth and profitability profile.Recent updates
Mise à jour du récit • May 19
AMBU B: Lower P/E Expectations Will Support Future Upside Repricing
Analysts have trimmed their price target on Ambu from DKK 110.34 to DKK 88.80, reflecting a more cautious stance following a downgrade in recent research. The revised target still assumes steady revenue growth and a lower future P/E multiple.Article d’analyse • May 09
Ambu A/S Just Missed EPS By 13%: Here's What Analysts Think Will Happen Next
As you might know, Ambu A/S ( CPH:AMBU B ) last week released its latest quarterly, and things did not turn out so...Mise à jour du récit • May 04
AMBU B: Higher Growth And Margins Are Expected To Support Future Upside
Analysts have reduced their price target on Ambu by DKK 12. This reflects updated views on discount rates, expected revenue growth, profit margins and future P/E assumptions.Mise à jour du récit • Apr 20
AMBU B: Reset P/E Assumptions Will Support Future Upside Repricing
Ambu's analyst price target has been reduced by DKK 12 to reflect updated views on its P/E assumptions, revenue growth profile and profitability, with analysts pointing to the recent DKK 12 target cut cited in Street research. Analyst Commentary JPMorgan's DKK 12 reduction in its Ambu price target reflects a reset of P/E expectations and a more cautious stance on the company's revenue growth and profitability profile.Mise à jour du récit • Apr 06
AMBU B: Refined Discount Rate And P/E Expectations Will Support Future Upside
Analysts have lowered their price target on Ambu by DKK 12. This reflects small adjustments to fair value, discount rate, revenue growth, profit margin and future P/E assumptions following recent research updates.Mise à jour du récit • Mar 22
AMBU B: Lower P/E Assumptions Will Support Upside If Execution Improves
Analysts have lowered their price target on Ambu by DKK 12 to reflect slightly adjusted assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E following the recent JPMorgan target cut to DKK 12. Analyst Commentary Bullish Takeaways Bullish analysts see the revised fair value and discount rate assumptions as a reset that could leave room for upside if Ambu delivers on its operational targets.Mise à jour du récit • Mar 08
AMBU B: Share Repurchase Mandate And Lowered Fair Value Will Support Upside
Analysts have trimmed their price target on Ambu by DKK 12 to reflect updated assumptions on fair value, discount rates and earnings expectations following recent research commentary. Analyst Commentary Bullish Takeaways Bullish analysts view the revised DKK 12 lower price target as still consistent with a supportive fair value range.Mise à jour du récit • Feb 22
AMBU B: Share Buybacks And Margin Discipline Will Support Future Upside
The analyst price target for Ambu has been trimmed by DKK 1 to DKK 138, as analysts factor in slightly more cautious assumptions on growth, margins and discount rates following recent price target adjustments, such as the DKK 12 cut highlighted by JPMorgan. Analyst Commentary Bullish analysts remain focused on how Ambu can justify its current valuation through consistent execution on its growth plans, even as some price targets, including the DKK 12 adjustment flagged by JPMorgan, are recalibrated.
Mise à jour du récit • Feb 08
AMBU B: Higher Risk Premium And Margin Pressure Will Reshape Share Outlook
The analyst price target for Ambu has been reduced from DKK 94.54 to DKK 78.00. This change reflects analysts’ updated assumptions on discount rate, revenue growth, profit margin and future P/E, as highlighted by recent Street research including a DKK 12 target cut.Article d’analyse • Feb 08
Earnings Miss: Ambu A/S Missed EPS By 8.7% And Analysts Are Revising Their Forecasts
Investors in Ambu A/S ( CPH:AMBU B ) had a good week, as its shares rose 3.3% to close at kr.87.90 following the...Mise à jour du récit • Jan 25
AMBU B: Share Repurchases And Dividend Policy Will Support Future Upside
Analysts have slightly reduced their price target on Ambu, citing modest revisions to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Together, these changes support a more cautious yet still constructive view on the shares.Mise à jour du récit • Jan 11
AMBU B: Share Buybacks And Dividend Policy Will Support Future Upside
Analysts now set Ambu's price target at €139, down from €147, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that adjust their valuation framework. What's in the News Ambu A/S is set to be removed from the OMX Copenhagen 20 Index, which may affect how some index and benchmark focused investors view or hold the stock (Key Developments).Article d’analyse • Jan 03
Ambu A/S' (CPH:AMBU B) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 37.7x Ambu A/S ( CPH:AMBU B ) may be sending very bearish signals at the...Mise à jour du récit • Dec 19
AMBU B: Dividend And Share Buybacks Will Drive Future Upside Potential
Analysts have trimmed their price target for Ambu slightly, lowering fair value by about 1 dollar per share as modestly slower expected revenue growth and profit margins are only partly offset by a slightly higher future P/E multiple and lower discount rate. What's in the News Ambu has launched a new share repurchase program starting December 10, 2025, allowing buybacks of up to 10% of its share capital under a mandate valid until December 13, 2027 (company announcement) The company announced an annual dividend of DKK 0.41 per share, payable on December 8, 2025, with an ex date of December 4 and record date of December 5, 2025 (company announcement) For fiscal 2025/26, Ambu issued guidance for 10% to 13% organic growth and an EBIT margin of 12% to 14%, or 14% to 16% excluding roughly 2 percentage points of tariff impacts (company guidance) Ambu reaffirmed its 2024/25 financial guidance, maintaining expectations for 12% to 14% organic revenue growth (company guidance) Valuation Changes Fair Value Estimate edged down slightly from DKK 115.59 to DKK 114.79 per share, reflecting a modestly lower fundamental valuation.Article d’analyse • Dec 12
An Intrinsic Calculation For Ambu A/S (CPH:AMBU B) Suggests It's 34% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Ambu fair value estimate is kr.130 Ambu's kr.85.60 share price...Mise à jour du récit • Dec 05
AMBU B: Dividend Initiation And Margin Outlook Will Support Future Upside
Analysts have modestly raised their price target on Ambu by DKK 0.00 to reflect a slightly higher discount rate and updated profitability assumptions, while maintaining largely unchanged views on long term growth and valuation multiples. What's in the News Ambu A/S announced an annual dividend of DKK 0.41 per share, payable on December 8, 2025, with ex-date December 4 and record date December 5, 2025 (Key Developments).Article d’analyse • Nov 27
We Think Shareholders Are Less Likely To Approve A Pay Rise For Ambu A/S' (CPH:AMBU B) CEO For Now
Key Insights Ambu's Annual General Meeting to take place on 3rd of December Salary of kr.8.01m is part of CEO Britt...Mise à jour du récit • Nov 21
AMBU B: Improved Margins And Dividend Outlook Will Support Bullish Momentum
Analysts have slightly lowered their fair value price target for Ambu from DKK 121.41 to DKK 115.59, citing modest decreases in projected revenue growth and profit margin expectations. What's in the News Ambu A/S announced an annual dividend of DKK 0.4100 per share.Mise à jour du récit • Nov 06
AMBU B: Higher Profit Margins Will Drive Hospital Efficiency Improvements
Analysts have revised their fair value estimate for Ambu down from DKK 130.70 to DKK 121.41. They cite a slightly higher discount rate, even though profit margin and revenue growth projections have improved.Article d’analyse • Oct 07
Ambu (CPH:AMBU B) Has More To Do To Multiply In Value Going Forward
To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...Article d’analyse • Aug 27
Ambu A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Investors in Ambu A/S ( CPH:AMBU B ) had a good week, as its shares rose 3.4% to close at kr.98.20 following the...Article d’analyse • Aug 11
Is Ambu A/S (CPH:AMBU B) Trading At A 35% Discount?
CPSE:AMBU B 1 Year Share Price vs Fair Value Explore Ambu's Fair Values from the Community and select yours Key...Article d’analyse • Jul 12
Should You Think About Buying Ambu A/S (CPH:AMBU B) Now?
Ambu A/S ( CPH:AMBU B ), is not the largest company out there, but it saw significant share price movement during...Article d’analyse • May 15
Ambu's (CPH:AMBU B) Earnings Offer More Than Meets The Eye
The stock was sluggish on the back of Ambu A/S' ( CPH:AMBU B ) recent earnings report. We have done some analysis, and...Article d’analyse • Mar 14
Is Now The Time To Put Ambu (CPH:AMBU B) On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Article d’analyse • Feb 02
Earnings Miss: Ambu A/S Missed EPS By 6.2% And Analysts Are Revising Their Forecasts
Ambu A/S ( CPH:AMBU B ) last week reported its latest quarterly results, which makes it a good time for investors to...Article d’analyse • Jan 27
Ambu (CPH:AMBU B) Will Want To Turn Around Its Return Trends
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...Article d’analyse • Jan 12
Revenues Tell The Story For Ambu A/S (CPH:AMBU B) As Its Stock Soars 27%
Ambu A/S ( CPH:AMBU B ) shareholders would be excited to see that the share price has had a great month, posting a 27...Article d’analyse • Dec 31
Is It Too Late To Consider Buying Ambu A/S (CPH:AMBU B)?
Ambu A/S ( CPH:AMBU B ), is not the largest company out there, but it received a lot of attention from a substantial...
Nouveau récit • Dec 16
Innovative aScope 5 Uretero And Sustainable Initiatives Will Accelerate Revenue Growth
Strategic focus on new high-value product launches and sustainability efforts could enhance revenue growth, product adoption, and brand perception while supporting long-term profitability.Article d’analyse • Nov 28
Here's Why It's Unlikely That Ambu A/S' (CPH:AMBU B) CEO Will See A Pay Rise This Year
Key Insights Ambu will host its Annual General Meeting on 4th of December CEO Britt Jensen's total compensation...Article d’analyse • Nov 13
Ambu's (CPH:AMBU B) Strong Earnings Are Of Good Quality
Ambu A/S ( CPH:AMBU B ) just reported healthy earnings but the stock price didn't move much. Our analysis suggests that...Article d’analyse • Nov 07
Earnings Miss: Ambu A/S Missed EPS By 54% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that Ambu A/S ( CPH:AMBU B ) filed its full-year result this time last week. The early...Article d’analyse • Sep 02
Ambu A/S Just Beat EPS By 15%: Here's What Analysts Think Will Happen Next
It's been a sad week for Ambu A/S ( CPH:AMBU B ), who've watched their investment drop 10% to kr.128 in the week since...Article d’analyse • Aug 06
Here's What's Concerning About Ambu's (CPH:AMBU B) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...Article d’analyse • Apr 06
Ambu A/S' (CPH:AMBU B) Subdued P/S Might Signal An Opportunity
With a median price-to-sales (or "P/S") ratio of close to 6.1x in the Medical Equipment industry in Denmark, you could...Article d’analyse • Mar 14
Returns On Capital Signal Tricky Times Ahead For Ambu (CPH:AMBU B)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...Article d’analyse • Feb 01
Results: Ambu A/S Exceeded Expectations And The Consensus Has Updated Its Estimates
Investors in Ambu A/S ( CPH:AMBU B ) had a good week, as its shares rose 2.9% to close at kr.115 following the release...Article d’analyse • Jan 02
A Piece Of The Puzzle Missing From Ambu A/S' (CPH:AMBU B) Share Price
It's not a stretch to say that Ambu A/S' ( CPH:AMBU B ) price-to-sales (or "P/S") ratio of 5.9x right now seems quite...Article d’analyse • Oct 31
Is Ambu A/S (CPH:AMBU B) Trading At A 42% Discount?
Key Insights Ambu's estimated fair value is kr.114 based on 2 Stage Free Cash Flow to Equity Ambu's kr.66.00 share...Rendement pour les actionnaires
| AMBU B | DK Medical Equipment | DK Marché | |
|---|---|---|---|
| 7D | 6.2% | 3.0% | 1.7% |
| 1Y | -32.6% | -27.7% | -16.1% |
Rendement vs Industrie: AMBU B a sous-performé le secteur Danish Medical Equipment qui a rapporté -27.7 % au cours de l'année écoulée.
Rendement vs marché: AMBU B a sous-performé le marché Danish qui a rapporté -16.1 % au cours de l'année écoulée.
Volatilité des prix
| AMBU B volatility | |
|---|---|
| AMBU B Average Weekly Movement | 4.9% |
| Medical Equipment Industry Average Movement | 4.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DK Market | 9.3% |
| 10% least volatile stocks in DK Market | 3.0% |
Cours de l'action stable: AMBU B n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Danish.
Volatilité au fil du temps: La volatilité hebdomadaire de AMBU B ( 5% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1937 | 5,200 | Britt Jensen | www.ambu.com |
Ambu A/S, société de technologie médicale, développe, produit et vend des dispositifs médicaux aux hôpitaux, aux cliniques et aux services de secours du monde entier. La société propose des produits d'anesthésie, de surveillance des patients et de diagnostic. Elle propose également des produits d'endoscopie, tels que des bronchoscopes, des rhinolaryngoscopes, des duodénoscopes, des gastroscopes, des cystoscopes et des unités d'affichage, ainsi que des produits de neurologie, notamment des électrodes EEG et EMG, des injections guidées par EMG et des produits de surveillance peropératoire.
Ambu A/S Résumé des fondamentaux
| AMBU B statistiques fondamentales | |
|---|---|
| Capitalisation boursière | DKK 18.04b |
| Bénéfices(TTM) | DKK 477.00m |
| Recettes(TTM) | DKK 6.10b |
37.8x
Ratio P/E3.0x
Ratio P/SLe site AMBU B est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| AMBU B compte de résultat (TTM) | |
|---|---|
| Recettes | DKK 6.10b |
| Coût des recettes | DKK 2.44b |
| Marge brute | DKK 3.66b |
| Autres dépenses | DKK 3.18b |
| Les revenus | DKK 477.00m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Aug 26, 2026
| Résultat par action (EPS) | 1.80 |
| Marge brute | 59.98% |
| Marge bénéficiaire nette | 7.81% |
| Ratio dettes/capitaux propres | 0.3% |
Quelles ont été les performances à long terme de AMBU B?
Voir les performances historiques et les comparaisonsDividendes
0.6%
Rendement actuel des dividendes23%
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/25 15:38 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/09/30 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Ambu A/S est couverte par 14 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Michael Healy | Berenberg |
| Susannah Ludwig | Bernstein |